Healthcare Services

Eosinophilic asthma market projected to reach $6.92B by 2030 at 16.9% CAGR

April 21, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Does The Market Size Of The Eosinophilic Asthma Market Compare Between 2026 And 2030?

The eosinophilic asthma market has witnessed substantial growth in recent years. It is forecast to expand from $3.16 billion in 2025 to $3.71 billion in 2026, achieving a compound annual growth rate (CAGR) of 17.4%. The historical rise in this market can be attributed to elements such as poor response to inhaled steroids, an increase in asthma prevalence, the identification of eosinophil biomarkers, higher hospital asthma admissions, and the burden of chronic respiratory diseases.

The market for eosinophilic asthma is projected to experience swift expansion over the coming years. This market is anticipated to reach $6.92 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 16.9%. Several factors contribute to this growth during the forecast period, including the advancement of precision asthma treatments, the expansion of the biologic drug pipeline, enhanced biomarker-based diagnostic methods, the provision of personalized respiratory care, and the proliferation of specialty clinics. Key trends anticipated during this period encompass the increasing acceptance of biologic therapies, a heightened focus on severe asthma phenotypes, a growing need for targeted immunotherapy, the enlargement of specialized respiratory clinics, and a stronger emphasis on mitigating exacerbation rates.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

Which Drivers Are Supporting The Eosinophilic Asthma Market Growth?

The eosinophilic asthma market is anticipated to expand due to increasing smoking habits. These habits describe consistent patterns of tobacco product use, including frequency, context, and duration, which are often shaped by psychological, social, and environmental factors. Several elements contribute to the surge in smoking habits, such as elevated stress levels, targeted marketing by tobacco companies, insufficient public awareness regarding health risks, and cultural acceptance of smoking in certain communities. Eosinophilic asthma treatment, by reducing airway inflammation and improving lung function, can also support smoking cessation by alleviating respiratory issues that often lead individuals to continue smoking. Data from November 2025, provided by the UK-based Office for National Statistics, showed an increase in e-cigarette use among women in Great Britain, rising from 8.5% in 2023 to 10.0% in 2024. Additionally, daily e-cigarette consumption was most prevalent among those aged 25 to 34 years and 35 to 49 years in Great Britain, reaching 9.3% and 9.5% respectively, with an observed increase in both age brackets since 2023. Consequently, the growing prevalence of smoking is a key driver for the eosinophilic asthma market.

What Are The Different Segment Types In The Eosinophilic Asthma Market Segment Breakdown?

The eosinophilic asthma market covered in this report is segmented –

1) By Disease: Severe Eoisnophilic Asthma, Mild To Moderate Eosinophilic Asthma

2) By Treatment: Biologics, Bronchodilators, Corticosteroids, Immunomodulators, Other Treatments

3) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma, Late-Onset Eosinophilic Asthma

2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma, Intermittent Eosinophilic Asthma

Which Trends Are Expected To Impact The Eosinophilic Asthma Market?

Major companies within the eosinophilic asthma market are focused on developing innovative medications to target specific immune pathways, diminish inflammation, and enhance patient outcomes via individualized treatment strategies. A monoclonal antibody is a laboratory-engineered molecule designed to emulate the immune system’s capacity to combat harmful pathogens such as viruses and bacteria. These antibodies are created through a process involving the fusion of a specific antibody-producing cell with a cancerous cell, allowing for the generation of large quantities of identical antibodies. For instance, in August 2024, AstraZeneca plc, a biopharmaceutical company based in the UK, announced the approval of Fasenra by China’s National Medical Products Association, a government agency located in China, for the treatment of severe eosinophilic asthma. It is specifically prescribed for individuals with severe eosinophilic asthma, a condition marked by elevated levels of eosinophils, which can lead to inflammation and a worsening of asthma symptoms. Fasenra is a monoclonal antibody that uniquely targets and depletes eosinophils. It strengthens the immune system’s ability by binding to the IL-5 receptor on eosinophils, thereby reducing eosinophil levels in the blood and tissues. The prescribed dosing regimen comprises an initial loading phase followed by maintenance doses. Patients typically receive injections every four weeks for the first three doses, subsequently followed by injections every eight weeks.

Who Are The Well-Known Companies In The Eosinophilic Asthma Market?

Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A., Pfizer Inc., Merck & Co. Inc., Johnson & Johnson, Bayer AG, Eli Lilly and Company, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Cipla Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kyowa Kirin Co. Ltd., UCB S.A., 4D Pharma plc, MorphoSys AG, Avalo Therapeutics Inc.

Get The Full Eosinophilic Asthma Market Report:

https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

Which Geographic Region Dominates The Eosinophilic Asthma Market?

North America was the largest region in the eosinophilic asthma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Eosinophilic Asthma Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

Browse Through More Reports Similar to the Global Eosinophilic Asthma Market 2026, By The Business Research Company

Allergic Rhinitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/allergic-rhinitis-global-market-report

Anti Asthmatics And Copd Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Anti Asthmatics And Copd Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795